Advisory board · Dr. Javier Ivanova

04 Jul 2026 · In person · Dr. Javier Ivanova, Johns Hopkins · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0116—

Capture insight from this engagement

Location: Johns Hopkins
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients
Brain-metastasis subgroup data
Infusion-reaction management

Scientific content used

VOYAGE-1 pivotal data summary
PD-L1 testing pathway infographic

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Advisory board with radiation oncologist at Johns Hopkins. Discussed elderly / ecog 2 patients, brain-metastasis subgroup data, infusion-reaction management.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 5
Depth of exchange: 1
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0116

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
04 Sept 2026, 06:42 UTC	Create	JWJames Whitfield	topics	— → In progress	—	UI